Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Key Clinical Message: Administering azathioprine or infliximab for UC and AS treatment carries a significant risk of adverse reactions. Here, we present the case diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months, and subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.

Abstract: Drug-induced myopathy is an uncommon form of muscle injury that can arise in patients without preexisting muscle conditions when exposed to therapeutic doses of certain medications. Administering azathioprine or infliximab for ulcerative colitis (UC) and ankylosing spondylitis (AS) treatment carries a significant risk of adverse reactions, including drug-induced myopathy and increased susceptibility to opportunistic infections. However, occurrences of myopathy induced by the combination of azathioprine and infliximab are rarely reported in clinical practice. Here, we present the case of a 37-year-old male patient diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months. Despite the resolution of symptoms and improvement in intestinal mucosal inflammation observed via endoscopy, the patient subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126648PMC
http://dx.doi.org/10.1002/ccr3.8998DOI Listing

Publication Analysis

Top Keywords

azathioprine infliximab
24
drug-induced myopathy
16
infliximab treatment
8
ulcerative colitis
8
colitis ankylosing
8
ankylosing spondylitis
8
administering azathioprine
8
treatment carries
8
carries risk
8
risk adverse
8

Similar Publications

A 36-year-old woman with an otherwise unremarkable medical history was diagnosed with moderate to severe Crohn disease and was started on infliximab. One year later, infliximab was discontinued due to intolerance, and the patient began azathioprine and mesalazine treatment, achieving stable disease. Eight months after discontinuing infliximab, during a Crohn disease flare-up, an urgent abdominal CT examination was performed, partially documenting the lung bases.

View Article and Find Full Text PDF

Objective: To described clinical and genetic characteristics of 4 patients presenting A20 haploinsufficiency (HA20) treated at Children's hospital affiliated to Zhengzhou university from 2015 to 2024.

Methods: A retrospective analysis was conducted on the clinical data, genetic testing results, and treatment outcomes of four children with HA20 treated at the Children's hospital affiliated to Zhengzhou university from 2015 to 2024.

Results: All four patients developed symptoms before the age of 1 year, presenting with recurrent fever and abdominal pain with diarrhea.

View Article and Find Full Text PDF

Objectives: The clinical pathway for patients with moderate-to-severe Crohn's disease (CD) typically includes sequential pharmacologic treatment as well as surgery, but positioning of different therapies within these sequences remains challenging. Cost-utility analysis rarely captures these sequences and does not incorporate registry data on long-term effectiveness. In this study, we aim to overcome these limitations.

View Article and Find Full Text PDF

Medical therapies to prevent relapse of Crohn's disease after surgery: a systematic review and network meta-analysis.

J Gastrointest Surg

August 2025

Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, United States. Electronic address:

Background: Postoperative recurrence of Crohn's disease is common. Prophylactic medical treatment against recurrence is advocated, but the most effective regimen is still debatable. This network meta-analysis aimed to compare different types of medical treatments for trying to prevent Crohn's disease recurrence.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD) poses a major therapeutic challenge due to its chronic course and variable treatment responses. Genetic polymorphisms significantly influence drug efficacy, prompting this review to analyze their role in treatment non-response. A systematic literature search (PubMed/Scopus) using terms like "genetic polymorphism," "non-response," and "IBD" identified 25 relevant studies.

View Article and Find Full Text PDF